Characterization of polymyxin B-induced nephrotoxicity: Implications for dosing regimen design

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4625-4629

  Abdelraouf, Kamilia ^a   Braggs, Kirk H ^a   Yin, Taijun ^a,b   Truong, Luan D ^b   Hu, Ming ^a   Tam, Vincent H ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; POLYMYXIN B;

ACUTE KIDNEY TUBULE NECROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOTOXICITY; DRUG ACCUMULATION; DRUG TISSUE LEVEL; DRUG UPTAKE; EMBRYO; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY PARENCHYMA; KIDNEY TUBULE DAMAGE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; CELL SURVIVAL; CREATININE; DOGS; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; INJECTIONS, SUBCUTANEOUS; KAPLAN-MEIER ESTIMATE; KIDNEY TUBULAR NECROSIS, ACUTE; KIDNEY TUBULES, PROXIMAL; POLYMYXIN B; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 84865428411     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00280-12     Document Type: Article

References (27)

1. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. 2010. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin. Infect. Dis. 50:1568-1574.
2. Drusano GL, et al. 2007. Back to the future: using aminoglycosides again and how to dose them optimally. Clin. Infect. Dis. 45:753-760. (Pubitemid 47378891)
3. Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A. 2006. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gramnegative bacterial infections. Clin. Microbiol. Infect. 12:1227-1230. (Pubitemid 44762527)
4. Garnacho-Montero J, et al. 2003. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin. Infect. Dis. 36:1111-1118. (Pubitemid 36549630)
5. Garonzik SM, et al. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55:3284-3294.
6. Ingram PR, Lye DC, Fisher DA, Goh WP, Tam VH. 2009. Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int. J. Antimicrob. Agents 34:570-574.
7. Ingram PR, et al. 2008. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J. Antimicrob. Chemother. 62:168-171. (Pubitemid 351865892)
8. Johnson WD, Lang CM, Johnson MT. 1978. Fixatives and methods of fixation in selected tissues of the laboratory rat. Clin. Toxicol. 12:583-600. (Pubitemid 8406507)
9. Katz R. 1963. Renal and possibly hepatic toxicity from Coly-Mycin. Report of a case. Med. Ann. Dist. Columbia 32:408-413.
10. Ko KS, et al. 2007. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J. Antimicrob. Chemother. 60:1163-1167. (Pubitemid 47617772)
11. Koch-Weser J, et al. 1970. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann. Intern. Med. 72:857-868.
12. Kwa AL, et al. 2008. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn. Microbiol. Infect. Dis. 60:163-167.
13. Kwa AL, Tam VH, Falagas ME. 2008. Polymyxins: a review of the current status including recent developments. Ann. Acad. Med. Singapore 37:870-883.
14. Landman D, Bratu S, Alam M, Quale J. 2005. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J. Antimicrob. Chemother. 55:954-957. (Pubitemid 40883181)
15. Lodise TP, Lomaestro B, Graves J, Drusano GL. 2008. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents Chemother. 52:1330-1336. (Pubitemid 351521995)
16. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. 2009. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis. 49:507-514.
17. Moestrup SK, et al. 1995. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J. Clin. Invest. 96:1404-1413.
18. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. 2003. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob. Agents Chemother. 47:2659-2662. (Pubitemid 36919476)
19. Pogue JM, et al. 2011. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin. Infect. Dis. 53:879-884.
20. Price DJ, Graham DI. 1970. Effects of large doses of colistin sulphomethate sodium on renal function. Br. Med. J. 4:525-527.
21. Rice LB. 2007. Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria. Cleve. Clin. J. Med. 74(Suppl 4):S12-S20.
22. Ryan KJ, Schainuck LI, Hickman RO, Striker GE. 1969. Colistimethate toxicity. Report of a fatal case in a previously healthy child. JAMA 207:2099-2101.
23. Sobieszczyk ME, et al. 2004. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J. Antimicrob. Chemother. 54:566-569. (Pubitemid 39177490)
24. Tallgren LG, Liewendahl K, Kuhlbaeck B. 1965. The therapeutic success and nephrotoxicity of colistin in acute and chronic nephropathies with impaired renal function. Acta Med. Scand. 177:717-728.
25. Tam VH, et al. 2005. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:3624-3630. (Pubitemid 41233009)
26. Wallace SJ, et al. 2008. Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens. Antimicrob. Agents Chemother. 52:1159-1161. (Pubitemid 351358406)
27. Yuan Z, Tam VH. 2008. Polymyxin B: a new strategy for multidrugresistant Gram-negative organisms. Expert Opin. Invest. Drugs 17:661-668. (Pubitemid 351843610)